Figure S3 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis

Key Points

• PLT012, a humanized CD36-blocking antibody, enhances antitumor immunity against liver cancer.
• The study characterizes tumor-infiltrating lymphocytes and gene signatures following treatment with PLT012.
• Liver cancer mouse models showed increased immune activity against tumors post-PLT012 administration.
• These findings provide insights for potential therapeutic strategies targeting liver cancer and metastasis.